An Indian TB drugmaker has been hit with a WHO Notice of Concern but an independent audit carried out by its customer Svizera Europe disputes the GMP violations raised.
Investments in technologies and capabilities are reaping rewards says Catalent which will continue placing “disproportionate emphasis” on its biologics business.
Sanofi wants to expand its inhalable drug production site in Cheshire, UK to increase capacity for both its own brand drug production operations and its contract manufacturing business.
Clinical trial inspectors will need a University degree and familiarity with modern data management principles under European Commission proposals.
Ongoing consolidation in the CDMO industry is beneficial for Catalent, the firm says as it reports a fourth quarter marred by weak currencies.